Molecule.one
- Company typePrivate
- Founded2019
- HeadquartersWarsaw, Poland
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Molecule.one firmographics
Firmographics- Name
- Molecule.one
- Legal name
- Molecule One Inc.
- Website
- https://molecule.one
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where Molecule.one is headquartered
LocationHeadquarters
- HQ city
- Warsaw
- HQ country
- Poland
- HQ region
- Europe
Offices3 records
Markets served
Molecule.one business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Maria™ AI Platform Licensing: Licensing the Maria™ AI platform to CDMOs, Pharma, Biotechs and Frontier AI companies for deep autonomous research chemistry projects. The platform discovers and delivers synthetic pathways, customized compound spaces, and hit series with confirmed activity.
- Research Partnerships: Strategic collaborations with pharmaceutical and biotech companies for synthesis planning, compound discovery, and AI-driven drug development. Includes delivery of efficient synthetic pathways and experimentally validated outputs.
- Synthesis Planning Software: Commercial software based on deep learning models for chemical synthesis planning, first launched commercially in 2019.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
Molecule.one product offering
Product offeringCore offering
Molecule.one develops the Maria™ AI platform, which combines frontier chemistry models in an agentic framework, a proprietary microliter-scale high-throughput experimentation laboratory, and a large proprietary reaction dataset to enable near-autonomous chemistry research. The company licenses this platform to pharmaceutical, biotechnology, CDMO, and frontier AI customers for synthesis planning, customized compound-space design, and experimentally validated hit discovery. It also delivers multi-year research partnership engagements that produce synthetic pathways and validated compound outputs.
Product overview
Molecule.one offers the Maria™ platform, a unified system that unites AI, Lab, and Data to power near-autonomous chemistry research. The platform consists of three integrated components: Maria AI (frontier chemistry models in an agentic framework), Maria Lab (micro-liter scale HTE laboratory operating at 12,000 reactions per week), and Maria Data (proprietary dataset of 300,000+ reactions). The Retrosynthesis Platform and RetroTrim ensemble system provide trustworthy AI-driven synthesis planning that has won the $1M Standard Industries AI Challenge. The system achieves a closed loop where AI proposes experiments, the lab runs them at scale, and resulting data improves the AI models.
Differentiator
Problem solved
Functional benefit
Brands
- Maria AI: Frontier chemistry models combined in an agentic framework to solve chemical problems and discover new chemistry
- Maria Lab
- Maria Data
Products and services
- Maria™ AI Platform Unified AI platform combining frontier chemistry models in an agentic framework (Maria AI), a proprietary microliter-scale high-throughput experimentation lab (Maria Lab, 12,000+ reactions per week), and a proprietary dataset of 300,000+ reactions with 100x wider building-block diversity (Maria Data). Licensed to pharmaceutical, biotech, CDMO, and frontier AI customers for synthesis planning, customized compound space design, and experimentally validated hit discovery.
- Retrosynthesis Platform AI-powered synthesis planning tool that uses deep neural networks, including the RetroTrim ensemble (Reaction Prior, GraphScore, Retrieval Score), to generate and evaluate creative synthetic routes for target molecules and eliminate hallucinations in retrosynthesis. Delivered to enterprise customers and used internally for autonomous chemistry discovery including Chan-Lam coupling improvement with OpenAI.
Quantifiable outcome
- Mean yield improvement from 16.6% to 25.2% in Chan-Lam coupling for primary sulfonamides using AI-identified TEMPO additive
- +5 more outcomes
Companies that use Molecule.one
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles4 records
Molecule.one technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature10 records
Molecule.one partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship and core.
- OpenAIflagshipConnected GPT-5.4 model to Molecule.one's Maria AI system and high-throughput laboratory to autonomously improve Chan-Lam coupling reactions. AI identified TEMPO as additive improving mean yields from 16.6% to 25.2%. Ran 10,080 reactions across two cycles over three months - first chemistry discovery where AI proposed novel experiment that held up in lab.
- W. R. Grace & Co.flagshipMulti-year strategic agreement to accelerate drug development and enhance chemical manufacturing, focusing on synthesizing peptide building blocks using Molecule.one's AI platform. Result of winning the $1M Standard Industries AI Challenge.
- Standard IndustriesflagshipWon $1 million AI Challenge organized by Standard Industries and W.R. Grace for advancements in AI-assisted molecular synthesis and retrosynthesis processes.
- CAS (Chemical Abstracts Service)coreStrategic collaboration to accelerate drug discovery and develop the world's best platform for Synthetic Accessibility Scoring. CAS provides access to world's largest database of chemical reactions.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Molecule.one competitors and assessment
Company assessmentMarket position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key highlights7 records
Customer concentration
Molecule.one social profiles
Digital presenceMolecule.one financial estimates
Financial estimateRevenue estimate
Valuation estimate
Molecule.one leadership team
Management profileNumber of profiles
Profiles12 records
Molecule.one funding detail
Funding detailFunding overview
Funding rounds4 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Molecule.one M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Molecule.one
What does Molecule.one do?
Molecule.one develops the Maria™ AI platform, which combines frontier chemistry models in an agentic framework, a proprietary microliter-scale high-throughput experimentation laboratory, and a large proprietary reaction dataset to enable near-autonomous chemistry research. The company licenses this platform to pharmaceutical, biotechnology, CDMO, and frontier AI customers for synthesis planning, customized compound-space design, and experimentally validated hit discovery. It also delivers multi-year research partnership engagements that produce synthetic pathways and validated compound outputs.
Is Molecule.one a public or private company?
Molecule.one is a private company. It is classified as venture growth investor backed and is currently operating.
When was Molecule.one founded?
Molecule.one was founded in 2019. It employs 11 to 50 people.
Where is Molecule.one based?
Molecule.one is headquartered in Warsaw, Poland, in the Europe region.
How does Molecule.one make money?
Three revenue lines are on record. Maria™ AI Platform Licensing is the primary driver. The others are research Partnerships and synthesis Planning Software.
Does Molecule.one have an API?
No public API is recorded for Molecule.one.